Losartan and Transitional cell carcinoma - a phase IV clinical study of FDA data

Summary:

Transitional cell carcinoma is reported as a side effect among people who take Losartan (losartan potassium), especially for people who are male, 60+ old, also take Fentanyl, and have Type 2 diabetes.

The phase IV clinical study analyzes which people have Transitional cell carcinoma when taking Losartan. It is created by eHealthMe based on reports of 170,768 people who have side effects when taking Losartan from the FDA, and is updated regularly.

What is Losartan?

Losartan has active ingredients of losartan potassium. It is often used in high blood pressure. eHealthMe is studying from 177,692 Losartan users. Check the latest studies of Losartan.

What is Transitional cell carcinoma?

Transitional cell carcinoma (cancer tumour inner most layer of urinary system) is found to be associated with 186 drugs and 268 conditions by eHealthMe. Check the latest studies of Transitional cell carcinoma.

On Aug, 13, 2026

170,768 people reported to have side effects when taking Losartan.
Among them, 15 people (0.01%) have Transitional cell carcinoma.

Could Losartan cause Transitional cell carcinoma?

Among these 15 people:

What is the gender of people who have Transitional cell carcinoma when taking Losartan? *

female: 13.33 %
male: 86.67 %

What is the age of people who have Transitional cell carcinoma when taking Losartan? *

What are other drugs people take besides Losartan? *

What are other side effects people have besides Transitional cell carcinoma? *

Fatigue (feeling of tiredness): 2 people, 13.33%
Rectal Cancer (cancer of rectum): 2 people, 13.33%
Urinary Bladder Polyp: 2 people, 13.33%
Vaginal Stricture: 1 person, 6.67%
Hypocalcaemia (levels of calcium in blood serum are abnormally low): 1 person, 6.67%
Bradycardia (abnormally slow heart action): 1 person, 6.67%
Chest Pain: 1 person, 6.67%
Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall): 1 person, 6.67%
Essential Hypertension (primary hypertension): 1 person, 6.67%
Eye Disorder: 1 person, 6.67%

What are the existing conditions these people have? *

Insomnia (sleeplessness): 2 people, 13.33%
Hoarseness Or Changing Voice: 2 people, 13.33%
Prostate Cancer: 2 people, 13.33%
Diabetes: 2 people, 13.33%
Neoplasm Malignant (cancer tumour): 2 people, 13.33%
Dyslipidaemia (abnormal amount of lipids): 2 people, 13.33%
Musculoskeletal Chest Pain (pain in chest muscle or nerve or bones): 2 people, 13.33%
Multiple Myeloma (cancer of the plasma cells): 2 people, 13.33%
Herpes Zoster: 2 people, 13.33%
Type 2 Diabetes: 2 people, 13.33%

* Approximation only. Some reports may have incomplete information.

Do you take Losartan and have Transitional cell carcinoma?

- Check whether Transitional cell carcinoma is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Losartan:

Losartan (177,692 reports)

Browse all side effects of Losartan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Transitional cell carcinoma:

Transitional cell carcinoma (186 drugs)

Browse all the conditions that are associated with Transitional cell carcinoma:

Transitional cell carcinoma (268 conditions)

Related publications that referenced our studies

Lai SW, Lin HF, Lin CL, Liao KF, "No association between losartan use and acute pancreatitis in hypertensive patients", Eur J Hosp Pharm, 2017 Mar .
Lai SW, Lin HF, Lin CL, Liao KF, "No association between losartan use and acute pancreatitis in hypertensive patients", Eur J Hosp Pharm, 2017 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on losartan potassium (the active ingredients of Losartan) and Losartan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.